Trial reportGut2003
Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans.
Trial report in Gut, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review.Frontiers in psychiatry · 2020Pooled it
- Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.Neurogastroenterology and motility · 2007Trial
- Visceral response to acute retrograde gastric electrical stimulation in healthy human.World journal of gastroenterology · 2005Trial
- Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.Best practice & research. Clinical rheumatology · 2026Review
- Efficacy and safety of octreotide versus somatostatin therapy after CRS + HIPEC in patients with peritoneal carcinomatosis.Discover oncology · 2026Article
- Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach.Expert review of clinical immunology · 2024Review
- Review
- Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity.International journal of molecular sciences · 2020Review
- Reproducibility of gastric emptying assessed with scintigraphy in patients with upper GI symptoms.Neurogastroenterology and motility · 2018Article
- The gut sensor as regulator of body weight.Endocrine · 2015Review
- Current management strategies and emerging treatments for functional dyspepsia.Nature reviews. Gastroenterology & hepatology · 2013Review
- Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants.Neurogastroenterology and motility · 2012Article
- Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits.Patient preference and adherence · 2012Article
- Effects of octreotide on glucose transporter type 2 expression in obese rat small intestine.World journal of gastroenterology · 2011Article
- Pathophysiology, diagnosis and management of postoperative dumping syndrome.Nature reviews. Gastroenterology & hepatology · 2009Review
- Use of somatostatin analogues in obesity.Drugs · 2008Review
- Review
- The TANTALUS system for obesity: effect on gastric emptying of solids and ghrelin plasma levels.Obesity surgery · 2007Article
- Review
- Chronic Intestinal Pseudo-Obstruction in Systemic Sclerosis: An Uncommon Presentation.Case reports in gastroenterologyArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPharmacological approaches to alter satiation may have an impact on functional upper gastrointestinal disorders and potentially change food intake in obesity.
aimOur aim was to compare the effects of two doses of octreotide and placebo on postprandial symptoms, gastric accommodation, and gastric emptying using validated non-invasive techniques.
methodsIn a randomised, parallel group, two dose, double blind, placebo controlled study, 39 healthy participants (13 per group) were randomised to 30 or 100 micro g octreotide or placebo, administered subcutaneously, 30 minutes before each study. Studies were performed on three separate days and included scintigraphic gastric emptying of solids and liquids, (99m)Tc SPECT imaging to measure fasting stomach volume and gastric accommodation following a 300 ml Ensure meal, and a standardised nutrient drink test to measure maximum tolerated volume and postprandial symptoms.
resultsRelative to placebo, both doses of octreotide delayed gastric emptying of solids (not liquids), increased fasting gastric volume, reduced the change in gastric volume post meal, and decreased the sensation of fullness after a satiating meal.
conclusionThe somatostatin analogue octreotide significantly alters human gastric functions, including inhibition of the normal reflex responses of gastric volume increase and emptying of the meal. These pharmacological effects suggest studies of the medication in disorders of satiation, including obesity and dyspepsia, are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.